Description
Stanozolol Oil is the oily injection form of Stanozolol (Winstrol). Unlike the classical aqueous suspension (Winstrol Water), the substance here is dissolved in oily vehicle, enabling smoother pharmacokinetics and less post-injection inflammation.
Per study reports pharmacology remains identical to all Stanozolol forms: dihydrotestosterone derivative with pyrazole ring, resistant to aromatization and 5α-reduction, strong SHBG lowering. This yields the classical dry cutting profile with reduced subcutaneous water retention.
The oily injection has two important properties: first, it reduces first-pass hepatic metabolism compared to oral tablets. Second, it avoids the microcrystal-related post-injection inflammation of the aqueous suspension - however, Stanozolol remains substantially more hepatotoxic in oil form than most injection anabolics because the 17α-methyl group acts systemically.
Pharmacokinetically the oily form has a longer half-life (~24 hours) than the oral tablet (~9 hours). Once- to twice-daily injections suffice.
Known effects: dry muscle quality, joint dryness (classical Winstrol effect), HDL drop, ALT/AST elevation (less pronounced than oral but present), HPG suppression.
In recreational research practice Stanozolol Oil is positioned as a more practical alternative to the aqueous suspension - less PIP, less injection-site issues.
Stanozolol is on the WADA banned list.
You can order Stanozolol Oil as an oily injection solution in 10-pack at 50mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Stanozolol Oil bypasses the first-pass hepatic metabolism of the oral tablet - but Stanozolol remains 17-alpha-methylated and thus, even in oil form, substantially more hepatotoxic than most injection anabolics.
Documented in studies and the application literature:
- Hepatotoxicity: the 17-alpha-methyl group acts systemically. ALT/AST elevations are documented that are less pronounced than under the oral form but remain present.
- No aromatization: Stanozolol is resistant to aromatization and 5-alpha-reduction. This yields a dry profile, and the literature also describes pronounced joint dryness as a classical Winstrol effect.
- Lipid profile: a marked HDL drop is documented in studies, the substance shifts the lipid profile unfavorably.
- Suppression of endogenous production: Stanozolol suppresses the HPG axis, a reduced endogenous testosterone production is documented. A test base is customary in research practice.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Contrasting effects of testosterone and stanozolol on serum lipoprotein levels - JAMA 1989, Thompson et al: classical study on HDL drop under stanozolol.
- Response of human skeletal muscle to the anabolic steroid stanozolol - BMJ 1988, Kuipers et al: effects on muscle protein metabolism.
- Hereditary angioedema: safety of long-term stanozolol therapy - Journal of Allergy and Clinical Immunology 2007, Sloane et al: long-term safety data from clinical indication.
- Effects of the anabolic steroid stanozolol on growth and protein metabolism in the rat - Journal of Endocrinology 1987, Karl et al: preclinical data on anabolic effects.
- Simultaneous immunochemical detection of stanozolol and the main human metabolite, 3’-hydroxy-stanozolol, in urine and serum samples - Analytical Biochemistry 2008, Lood et al: doping detection and metabolite profile.
